<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychiatry Investig</journal-id><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Psychiatry Investigation</journal-title></journal-title-group><issn pub-type="ppub">1738-3684</issn><issn pub-type="epub">1976-3026</issn><publisher><publisher-name>Korean Neuropsychiatric Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22216049</article-id><article-id pub-id-type="pmc">3246147</article-id><article-id pub-id-type="doi">10.4306/pi.2011.8.4.372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Electroencephalographic Abnormalities in Clozapine-Treated Patients: A Cross-Sectional Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goyal</surname><given-names>Nishant</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Praharaj</surname><given-names>Samir Kumar</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Desarkar</surname><given-names>Pushpal</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nizamie</surname><given-names>Haque</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Senior Resident, Centre for Cognitive Neurosciences, Central Institute of Psychiatry, Kanke, Ranchi, Jharkhand, India.</aff><aff id="A2"><label>2</label>Department of Psychiatry, Kasturba Medical College, Manipal, Karnataka, India.</aff><aff id="A3"><label>3</label>Consultant Child and Adolescent Psychiatrist, Oxfordshire and Buckinghamshire Mental Health NHS Foundation Trust, Boundary Brook House (Park Hospital), Churchill Drive, Headington, Oxford, OX3 7LQ, UK.</aff><aff id="A4"><label>4</label>Professor of Psychiatry, In Charge Center for Cognitive Neurosciences, Central Institute of Psychiatry, Kanke, Ranchi, Jharkhand, India.</aff><author-notes><corresp>Correspondence: Samir Kumar Praharaj, MD, DPM. Assistant Professor, Department of Psychiatry, Kasturba Medical College, Manipal, Karnataka, India. Tel: +91-8971026304, Fax: +91-820-2571930, <email>samirpsyche@yahoo.co.in</email>; <email>psynishant@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>08</day><month>12</month><year>2011</year></pub-date><volume>8</volume><issue>4</issue><fpage>372</fpage><lpage>376</lpage><history><date date-type="received"><day>29</day><month>1</month><year>2011</year></date><date date-type="rev-recd"><day>21</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Korean Neuropsychiatric Association</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The objective of our study was to examine the electroencephalogram (EEG) abnormalities associated with clozapine treatment. It was a cross-sectional study on 87 psychiatric patients on clozapine treatment. 32 channel digital EEG was recorded and analysed visually for abnormalities. EEG abnormalities were observed in 63.2% of patients. Both slowing and epileptiform activities were noted in 41.4% of patients. The EEG abnormalities were not associated with dose or duration of clozapine exposure.</p></abstract><kwd-group><kwd>Clozapine</kwd><kwd>EEG abnormalities</kwd><kwd>Seizures</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Clozapine is a dibenzodiazepine derivative which has receptor blocking activity at dopamine D<sub>1</sub> and D<sub>4</sub> as well as serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptors.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref> It is an atypical antipsychotic that has been shown to be effective in treating patients with refractory schizophrenia.<xref ref-type="bibr" rid="B3">3</xref> Clozapine also is less likely to cause extrapyramidal adverse effects including tardive dyskinesia than other antipsychotics.<xref ref-type="bibr" rid="B4">4</xref> However, it has propensity to cause severe adverse effects such as agranulocytosis (1-2%)<xref ref-type="bibr" rid="B5">5</xref> and an unusually high incidence of seizures.<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></p><p>Recent estimates of incidence of clozapine-induced seizures vary from 1.3%<xref ref-type="bibr" rid="B8">8</xref> to 2.8%.<xref ref-type="bibr" rid="B9">9</xref> Even higher occurrence rates of seizures have been reported in more selected populations such as state hospital patients<xref ref-type="bibr" rid="B10">10</xref> or brain injured patients.<xref ref-type="bibr" rid="B11">11</xref> There is evidence that the risk for seizures is dose-related,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B12">12</xref> although seizures can occur in all dose ranges<xref ref-type="bibr" rid="B10">10</xref> and even at very low doses.<xref ref-type="bibr" rid="B13">13</xref></p><p>Electroencephalogram (EEG) abnormalities have been reported to occur frequently in several retrospective studies of patients treated with clozapine;<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B18">18</xref> it ranges from 53%<xref ref-type="bibr" rid="B17">17</xref> and 59%<xref ref-type="bibr" rid="B15">15</xref> to 74%.<xref ref-type="bibr" rid="B18">18</xref> Generalized slowing has been reported as the most prominent finding, followed by epileptiform activities such as spike-waves and sharp activities.<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref> Several but not all studies found EEG changes associated with clozapine to be dose-related.<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B20">20</xref> Furthermore, studies have shown that the plasma levels of clozapine predict pathological EEG changes as well as the occurrence of seizures.<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref> Some of these seemingly contradictory observations might be explained by clozapine's wide range of plasma level for a given dose.<xref ref-type="bibr" rid="B21">21</xref> Volavka et al.<xref ref-type="bibr" rid="B23">23</xref> reported that clozapine differed from the other antipsychotics by producing more EEG slowing and epileptiform activity. The aim of our study was to explore and characterize the EEG abnormalities associated with clozapine treatment.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This was a cross-sectional study conducted at Center for Cognitive Neurosciences, Central Institute of Psychiatry, Ranchi, India. Sample consisted of 87 patients on clozapine treatment for various psychiatric disorders. All the patients were receiving clozapine for at least two weeks. Patients with history of seizures in the recent past were excluded from the study. Digital EEG was recorded in awake state with eyes closed using 21 Ag-AgCl electrodes (32 channels) placed according to the international 10-20 system using Neurofax EEG-9000 (Nihon Kohden, Japan) amplifiers (sampling rate 512 Hz, TC 0.1 Sec., HFF 70 Hz) with linked ear electrodes as reference. Three minutes of hyperventilation as well as photic stimulation in different frequencies were also obtained. Visual analysis of the EEG was carried out by the author NG, having experience in EEG interpretation after appropriate training, to characterize background activity as well as to identify slow waves and epileptiform activity (spike-waves, polyspike-waves or sharp waves) and their localization. EEG abnormalities were categorized on the basis of duration of abnormalities in 95 to 100 epochs each of 10 seconds duration in real time that were characterized as 'mild' (&#x0003c;25% of epochs), 'moderate' (25-50% of epochs), and 'severe' (&#x0003e;50% of epochs or polyspikes).</p><p>The data obtained were analyzed with Statistical Package for Social Sciences-version 10.0 for Windows&#x000ae; (SPSS Inc., Chicago, IL, USA). Continuous variables were analyzed using independent sample 't' test and categorical data was analyzed using Pearson's chi-square test. Level of significance was set at p&#x0003c;0.05 (two-tailed). Logistic regression analysis (backward conditional method) was carried out with presence or absence of EEG abnormality as outcome variable. Age, gender, clozapine dose, duration on clozapine and medications were entered as predictor variables.</p></sec><sec><title>RESULTS</title><p>Sample consisted of 76 (87.4%) males and 11 (12.6%) females. Mean age of the sample was 32.76 (SD 11.10) years and mean duration of illness was 92.39 (SD 64.79) months. Entire sample was right handed. Daily clozapine doses varied from 25 to 800 (mean 293.10, SD 172.55) mg/day and mean duration on clozapine was 15.07 (SD 8.98) weeks. Fifty-six (64.4%) patients were on clozapine alone, whereas 19 (21.8%) received valproate, 7 (8%) other antipsychotics and 5 (5.7%) antidepressants along with clozapine. Sixty-three (72.4%) had schizophrenia, 9 (10.3%) had mood disorders and 6 (6.9%) had schizoaffective disorder. Five (5.7%) patients had past history of epilepsy during childhood and three (3.4%) patients had head injury or central nervous system infection. EEG abnormalities associated with clozapine are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. There was no difference in clozapine dose between patients with or without EEG abnormalities (t=0.96, p=0.342). Abnormal EEG was found in 34 (66.7%) patients receiving clozapine more than 300 mg/day, whereas it was seen in 21 (58.3%) patients receiving clozapine less than 300 mg/day. Among those receiving clozapine 100 mg or less per day (n=21), EEG was abnormal in 13 (61.9%) patients, whereas in those receiving clozapine 50 mg or less per day (n=12) and 25 mg or less per day (n=7), abnormal EEG was found in 6 (50%) and 4 (57.1%) patients, respectively. Abnormal EEG was found in 38 (67.9%), 11 (57.9%), 3 (42.9%) and 3 (60%) patients, among those receiving clozapine only, clozapine with sodium valproate, clozapine with antipsychotics and clozapine with antidepressants, respectively.</p><p>There was no difference in the frequency of EEG abnormalities (&#x003c7;<sup>2</sup>=1.45, p=0.228), presence of slow waves (&#x003c7;<sup>2</sup>=0.14, p=0.707) or epileptiform activities (&#x003c7;<sup>2</sup>=0.69, p=0.406) among patients receiving clozapine alone or clozapine with other drugs. There was no significant difference in age, sex, duration of illness and duration on clozapine treatment between the patients with or without EEG abnormalities (<xref ref-type="table" rid="T2">Table 2</xref>). Thirty-eight (69.1%) patients out of 63 patients with schizophrenia had abnormal EEG, although it was not significantly higher than patients with other diagnoses (&#x003c7;<sup>2</sup>=0.83, p=0.36). None of the patients developed clinical seizures. Logistic regression analysis did not identify any significant predictors of EEG abnormalities (<xref ref-type="table" rid="T3">Table 3</xref>).</p></sec><sec><title>DISCUSSION</title><p>The overall frequency of EEG abnormality was high (63.2%) in our study, that is consistent with the existing literature. EEG abnormalities occurred in 66.7% of patients receiving more than clozapine 300 mg/day; similar rates (72%) were reported earlier.<xref ref-type="bibr" rid="B14">14</xref> Treves and Neufeld<xref ref-type="bibr" rid="B24">24</xref> had found EEG abnormalities in 64% of patients under clozapine at 300 mg/day. Slowing of EEG in theta and delta range has been more frequent as com-pared to epileptiform activities in most studies,<xref ref-type="bibr" rid="B19">19</xref> whereas, in our study both were equally prevalent (-40%).</p><p>In their retrospective review, Gunther et al.<xref ref-type="bibr" rid="B17">17</xref> found a dose dependent relationship between clozapine dose and EEG slowing, with 92% of 283 patients receiving more than 600 mg clozapine exhibiting diffuse slowing. Liukkonen et al.<xref ref-type="bibr" rid="B25">25</xref> reported background disturbance in 11, paroxysmal slow wave activity in 8, and epileptiform discharges in 4 out of 12 patients; patients with epileptiform discharges were on clozapine 300-700 mg daily. In our study no such association was found. Nevertheless, moderate to severe abnormalities were more frequent in our study. Interestingly, EEG abnormalities were present in more than 50% patients, even in those receiving lower doses of clozapine (less than 100, 50 or 25 mg per day). This finding underscores the importance of EEG monitoring in patients on lower doses of clozapine. However, these EEG abnormalities are not specific and the epileptiform activity is not necessarily associated with seizures, as observed in our study.</p><p>Quantitative EEG studies have reported an increase in theta and delta power and coherence changes in theta band following clozapine treatment.<xref ref-type="bibr" rid="B26">26</xref> In that study, changes of coherence were correlated with changes on the Brief Psychiatric Rating Scale score, thus to clinical improvement. In a case study, sharp-slow wave activity was found bilaterally over frontal regions, and further source analysis localized these to the deep medial frontal region.<xref ref-type="bibr" rid="B27">27</xref> Further studies are required to characterize these EEG changes prospectively.</p><p>The mechanism of clozapine-induced seizure is not known, although its effect on gamma-aminobutyric acid A (GABA<sub>A</sub>) receptors<xref ref-type="bibr" rid="B28">28</xref> has been implicated. The other possible mechanisms include its action on nicotinic acetylcholine receptors,<xref ref-type="bibr" rid="B29">29</xref> glutamate N-methyl-D-aspartate (NMDA) receptors,<xref ref-type="bibr" rid="B3">3</xref> 0 serotonin 5-HT<sub>2A</sub><xref ref-type="bibr" rid="B31">31</xref> and strychnine-sensitive glycine receptors33 that merits further evaluation. In a mouse model, expression of immediate early gene such as <italic>c-fos</italic> has been found in number of subcortical sites and in orbital cortex of clozapine kindled myoclonic jerks.<xref ref-type="bibr" rid="B33">33</xref></p><p>Recently it has been suggested that EEG findings should not be excessively relied upon as there is no consensus on using EEG data as a guide for optimal dosing of clozapine.<xref ref-type="bibr" rid="B34">34</xref> Several studies<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref> including ours, show that EEG abnormalities may be present without any association with clinical seizures, in contrast to the study by Welch et al.<xref ref-type="bibr" rid="B18">18</xref> which suggested that the EEG is a sensitive indicator of clozapine toxicity and that changes such as the development of spikes and sharp waves indicate a high risk of convulsions. Larger studies are required to clarify this issue further.</p><p>In our cohort of 87 patients, EEG changes during clozapine therapy were common. Epileptiform activity was found in more than 40% of the patients and was of moderate to severe degree. However, in absence of baseline EEG, the issue of new onset abnormalities could not be clarified. Other limitation in our study includes heterogeneity of psychiatric diagnosis, the effect of which could not be examined due to small sample size. Also, serum clozapine levels were not measured in our study. It has been found that there are significant inter- and intra-individual variations in clozapine serum levels, for a given dose, and it has been attributed to its complex metabolism.<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B37">37</xref> A recent review<xref ref-type="bibr" rid="B38">38</xref> found that although there was evidence for strong relationship between clozapine dose and plasma level and occurrence of clozapine-induced EEG abnormalities, there was no statistically significant relationship between dose and occurrence of seizures. The authors concluded that there is insufficient data to suggest direct relation-ship of clozapine plasma level with occurrence of seizures, though they found three case reports suggesting very substantial risk of seizures with clozapine plasma levels exceeding 1,300 &#x000b5;g/L.<xref ref-type="bibr" rid="B38">38</xref> Nevertheless, therapeutic drug monitoring of clozapine has been suggested to be useful to identify signs of toxicity and onset of seizures.<xref ref-type="bibr" rid="B37">37</xref></p><p>It is also interesting to note that in Asian patients, the plasma clozapine levels were higher with a given dose of clozapine, compared to Caucasian patients, and the findings remained significant even after controlling for gender, body mass index, cigarette, alcohol and caffeine use.<xref ref-type="bibr" rid="B39">39</xref> Although ethnic differences in EEG abnormalities and seizures associated with clozapine has not been adequately studied, such variations might account for the differences in rates of EEG abnormalities. Two case studies<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref> described seizures occurring at lower clozapine doses in Asian patients, with very high serum levels in one report. In our study, frequent EEG abnormalities in those receiving lower doses of clozapine could reflect such ethnic variation, though such association is presumptive at best in the absence of plasma levels.</p><p>EEG abnormalities have also been reported to occur with typical as well as other atypical antipsychotics. One study<xref ref-type="bibr" rid="B42">42</xref> compared EEG abnormalities in those receiving antipsychotics (n=81) with normal healthy controls (n=30). Abnormal EEG was higher in those receiving olanzapine (35%) and haloperidol (23%) and was statistically significantly increased with dose in the olanzapine group, in contrast to patients treated with haloperidol, quetiapine or healthy subjects. Also, epileptiform activity was observed only in patients receiving olanzapine (11%). In another study43 on a larger sample (n=323), EEG abnormalities were most frequent with clozapine (47%), followed by olanzapine (38%), risperidone (28%), typical antipsychotics (14%) and none with quetiapine. In that study, comorbid disorders and older age were associated with higher risk, whereas there was no relationship with dose or clinical response.</p><p>There is some evidence to suggest a favorable clinical response in specific groups of patients (females, major depressive disorder) predicted by EEG abnormalities before clozapine treatment.<xref ref-type="bibr" rid="B44">44</xref> In another study,<xref ref-type="bibr" rid="B45">45</xref> pretreatment intrahemispheric asymmetry on EEG predicted short-term response to clozapine treatment in schizophrenia. Also, EEG abnormalities developing after clozapine treatment appeared to be associated with good response in another small study.<xref ref-type="bibr" rid="B46">46</xref></p><p>There is no consensus regarding antiepileptic prophylaxis in patients on clozapine without clinical seizures; some reports<xref ref-type="bibr" rid="B38">38</xref> advising use of these medications at a certain clozapine dose or plasma level (&#x0003e;500 &#x000b5;g/L) or appearance of clear epileptiform discharges on EEG. However, as shown in our report, seizures were absent in patients receiving higher clozapine doses, even in the presence of epileptiform discharges on EEG. Therefore, routine use of anticonvulsants may not be warranted in patients having EEG abnormalities, even in those having epileptiform discharges. Nevertheless, it appears prudent to monitor for the clinical appearance of seizures in these patients, specifically with higher doses.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coward</surname><given-names>DM</given-names></name><name><surname>Imperato</surname><given-names>A</given-names></name><name><surname>Urwyler</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>TG</given-names></name></person-group><article-title>Biochemical and behavioural properties of clozapine</article-title><source>Psychopharmacology (Berl)</source><year>1989</year><volume>99</volume><issue>Suppl</issue><fpage>S6</fpage><lpage>S12</lpage><pub-id pub-id-type="pmid">2573106</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Tol</surname><given-names>HH</given-names></name><name><surname>Bunzow</surname><given-names>JR</given-names></name><name><surname>Guan</surname><given-names>HC</given-names></name><name><surname>Sunahara</surname><given-names>RK</given-names></name><name><surname>Seeman</surname><given-names>P</given-names></name><name><surname>Niznik</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine</article-title><source>Nature</source><year>1991</year><volume>350</volume><fpage>610</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">1840645</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>JM</given-names></name><name><surname>Marder</surname><given-names>SR</given-names></name></person-group><article-title>Psychopharmacologic treatment of schizophrenia</article-title><source>Schizophr Bull</source><year>1993</year><volume>19</volume><fpage>287</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">8100642</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamminga</surname><given-names>CA</given-names></name><name><surname>Thaker</surname><given-names>GK</given-names></name><name><surname>Moran</surname><given-names>M</given-names></name><name><surname>Kakigi</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>XM</given-names></name></person-group><article-title>Clozapine in tardive dyskinesia: observations from human and animal model studies</article-title><source>J Clin Psychiatry</source><year>1994</year><volume>55</volume><issue>Suppl B</issue><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">7961550</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvir</surname><given-names>JM</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Safferman</surname><given-names>AZ</given-names></name><name><surname>Schwimmer</surname><given-names>JL</given-names></name><name><surname>Schaaf</surname><given-names>JA</given-names></name></person-group><article-title>Clozapine-induced agranulocytosis. Incidence and risk factors in the United States</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">8515788</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O</given-names></name><name><surname>Pacia</surname><given-names>SV</given-names></name></person-group><article-title>Seizures during clozapine therapy</article-title><source>J Clin Psychiatry</source><year>1994</year><volume>55</volume><issue>Suppl B</issue><fpage>153</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">7961562</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>E</given-names></name><name><surname>Binder</surname><given-names>RL</given-names></name></person-group><article-title>Clozapine and seizures</article-title><source>Am J Psychiatry</source><year>1990</year><volume>147</volume><fpage>1069</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">2375443</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacia</surname><given-names>SV</given-names></name><name><surname>Devinsky</surname><given-names>O</given-names></name></person-group><article-title>Clozapine-related seizures: experience with 5,629 patients</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>2247</fpage><lpage>2249</lpage><pub-id pub-id-type="pmid">7991106</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O</given-names></name><name><surname>Honigfeld</surname><given-names>G</given-names></name><name><surname>Patin</surname><given-names>J</given-names></name></person-group><article-title>Clozapine-related seizures</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>369</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">2006003</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Claussen</surname><given-names>AM</given-names></name></person-group><article-title>Seizures associated with clozapine treatment in a state hospital</article-title><source>J Clin Psychiatry</source><year>1994</year><volume>55</volume><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">8071267</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michals</surname><given-names>ML</given-names></name><name><surname>Crismon</surname><given-names>ML</given-names></name><name><surname>Roberts</surname><given-names>S</given-names></name><name><surname>Childs</surname><given-names>A</given-names></name></person-group><article-title>Clozapine response and adverse effects in nine brain-injured patients</article-title><source>J Clin Psychopharmacol</source><year>1993</year><volume>13</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">8354736</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>RW</given-names></name><name><surname>Conley</surname><given-names>RR</given-names></name></person-group><article-title>Seizures during clozapine therapy</article-title><source>Am J Psychiatry</source><year>1991</year><volume>148</volume><fpage>1265</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">1883011</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Goudemand</surname><given-names>M</given-names></name></person-group><article-title>Seizure with low doses of clozapine</article-title><source>Am J Psychiatry</source><year>1992</year><volume>149</volume><fpage>138</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">1728165</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isermann</surname><given-names>H</given-names></name><name><surname>Haupt</surname><given-names>R</given-names></name></person-group><article-title>EEG-changes in paranoid-hallucinatory psychoses treated with Clozapine</article-title><source>Nervenarzt</source><year>1976</year><volume>47</volume><fpage>268</fpage><pub-id pub-id-type="pmid">1272487</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spatz</surname><given-names>R</given-names></name><name><surname>Lorenzi</surname><given-names>E</given-names></name><name><surname>Kugler</surname><given-names>J</given-names></name><name><surname>R&#x000fc;ther</surname><given-names>E</given-names></name></person-group><article-title>The incidence of abnormal EEG patterns with clozapine therapy</article-title><source>Arzneimittelforschung</source><year>1978</year><volume>28</volume><fpage>1499</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">383098</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naber</surname><given-names>D</given-names></name><name><surname>Holzbach</surname><given-names>R</given-names></name><name><surname>Perro</surname><given-names>C</given-names></name><name><surname>Hippius</surname><given-names>H</given-names></name></person-group><article-title>Clinical management of clozapine patients in relation to efficacy and side effects</article-title><source>Br J Psychiatry Suppl</source><year>1992</year><volume>17</volume><fpage>54</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">1358128</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname><given-names>W</given-names></name><name><surname>Baghai</surname><given-names>T</given-names></name><name><surname>Naber</surname><given-names>D</given-names></name><name><surname>Spatz</surname><given-names>R</given-names></name><name><surname>Hippius</surname><given-names>H</given-names></name></person-group><article-title>EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 pa-tients</article-title><source>Pharmacopsychiatry</source><year>1993</year><volume>26</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">8415896</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>J</given-names></name><name><surname>Manschreck</surname><given-names>T</given-names></name><name><surname>Redmond</surname><given-names>D</given-names></name></person-group><article-title>Clozapine-induced seizures and EEG changes</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>1994</year><volume>6</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">7950347</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malow</surname><given-names>BA</given-names></name><name><surname>Reese</surname><given-names>KB</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Bogard</surname><given-names>PJ</given-names></name><name><surname>Malhotra</surname><given-names>AK</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Spectrum of EEG abnormalities during clozapine treatment</article-title><source>Electroencephalogr Clin Neurophysiol</source><year>1994</year><volume>91</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">7522149</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun-Scharm</surname><given-names>H</given-names></name><name><surname>Martinius</surname><given-names>J</given-names></name></person-group><article-title>EEG changes and seizures with clozapine medication in schizophrenic adolescents</article-title><source>Z Kinder Jugendpsychiatr</source><year>1991</year><volume>19</volume><fpage>164</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">1962511</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haring</surname><given-names>C</given-names></name><name><surname>Neudorfer</surname><given-names>C</given-names></name><name><surname>Schwitzer</surname><given-names>J</given-names></name><name><surname>Hummer</surname><given-names>M</given-names></name><name><surname>Saria</surname><given-names>A</given-names></name><name><surname>Hinterhuber</surname><given-names>H</given-names></name><etal/></person-group><article-title>EEG alterations in patients treated with clozapine in relation to plasma levels</article-title><source>Psychopharmacology (Berl)</source><year>1994</year><volume>114</volume><fpage>97</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">7846212</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freudenreich</surname><given-names>O</given-names></name><name><surname>Weiner</surname><given-names>RD</given-names></name><name><surname>McEvoy</surname><given-names>JP</given-names></name></person-group><article-title>Clozapine-induced electroencephalogram changes as a function of clozapine serum levels</article-title><source>Biol Psychiatry</source><year>1997</year><volume>42</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">9209730</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volavka</surname><given-names>J</given-names></name><name><surname>Abrams</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>MA</given-names></name><name><surname>Reker</surname><given-names>D</given-names></name></person-group><article-title>Hemispheric lateralization of fast EEG activity in schizophrenia and endogenous depression</article-title><source>Adv Biol Psychiatry</source><year>1981</year><volume>6</volume><fpage>72</fpage><lpage>75</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treves</surname><given-names>IA</given-names></name><name><surname>Neufeld</surname><given-names>MY</given-names></name></person-group><article-title>EEG abnormalities in clozapine-treated schizophrenic patients</article-title><source>Eur Neuropsychopharmacol</source><year>1996</year><volume>6</volume><fpage>93</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8791033</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liukkonen</surname><given-names>J</given-names></name><name><surname>Koponen</surname><given-names>JH</given-names></name><name><surname>Nousiainen</surname><given-names>U</given-names></name></person-group><article-title>Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment</article-title><source>Psychiatry Res</source><year>1992</year><volume>44</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">1480676</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>D</given-names></name><name><surname>Chaput</surname><given-names>Y</given-names></name><name><surname>Rodriguez</surname><given-names>JP</given-names></name><name><surname>Filion</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>D</given-names></name><name><surname>St-Denis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Quantified EEG changes associated with a positive clinical response to clozapine in schizophrenia</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>1995</year><volume>19</volume><fpage>861</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">8539424</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praharaj</surname><given-names>SK</given-names></name><name><surname>Venkatesh</surname><given-names>BG</given-names></name><name><surname>Sarkhel</surname><given-names>S</given-names></name><name><surname>Zia-Ul-Haq</surname><given-names>M</given-names></name><name><surname>Sinha</surname><given-names>VK</given-names></name></person-group><article-title>Clozapine-induced myoclonus: a case study and brief review</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2010</year><volume>34</volume><fpage>242</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">19833162</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squires</surname><given-names>RF</given-names></name><name><surname>Saederup</surname><given-names>E</given-names></name></person-group><article-title>Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors</article-title><source>Neurochem Res</source><year>1998</year><volume>23</volume><fpage>1283</fpage><lpage>1290</lpage><pub-id pub-id-type="pmid">9804284</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>SK</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Morales</surname><given-names>M</given-names></name><name><surname>Oz</surname><given-names>M</given-names></name></person-group><article-title>Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors</article-title><source>Neuropharmacology</source><year>2007</year><volume>52</volume><fpage>387</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">17161853</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvanov</surname><given-names>VL</given-names></name><name><surname>Wang</surname><given-names>RY</given-names></name></person-group><article-title>Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>289</volume><fpage>1000</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">10215680</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steward</surname><given-names>LJ</given-names></name><name><surname>Kennedy</surname><given-names>MD</given-names></name><name><surname>Morris</surname><given-names>BJ</given-names></name><name><surname>Pratt</surname><given-names>JA</given-names></name></person-group><article-title>The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors</article-title><source>Neuropharmacology</source><year>2004</year><volume>47</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">15380371</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clozapine inhibits strychnine-sensitive glycine receptors in rat hippocampal neurons</article-title><source>Brain Res</source><year>2009</year><volume>1278</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19409375</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>JR</given-names></name><name><surname>Denney</surname><given-names>D</given-names></name><name><surname>Szot</surname><given-names>P</given-names></name></person-group><article-title>Kindling with clozapine: behavioral and molecular consequences</article-title><source>Epilepsy Res</source><year>1996</year><volume>26</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">8985708</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Delva</surname><given-names>N</given-names></name></person-group><article-title>Clozapine-induced seizures: recognition and treatment</article-title><source>Can J Psychiatry</source><year>2007</year><volume>52</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">17688010</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risby</surname><given-names>ED</given-names></name><name><surname>Epstein</surname><given-names>CM</given-names></name><name><surname>Jewart</surname><given-names>RD</given-names></name><name><surname>Nguyen</surname><given-names>BV</given-names></name><name><surname>Morgan</surname><given-names>WN</given-names></name><name><surname>Risch</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Clozapine-induced EEG abnormalities and clinical response to clozapine</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>1995</year><volume>7</volume><fpage>466</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">8555749</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>RC</given-names></name><name><surname>Bromfield</surname><given-names>EB</given-names></name><name><surname>Khoshbin</surname><given-names>S</given-names></name></person-group><article-title>Clozapine-induced seizures and EEG abnormalities in ambulatory psychiatric patients</article-title><source>Ann Pharmacother</source><year>1998</year><volume>32</volume><fpage>1147</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">9825078</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood-Smith</surname><given-names>C</given-names></name><name><surname>Lubman</surname><given-names>DI</given-names></name><name><surname>Castle</surname><given-names>DJ</given-names></name></person-group><article-title>Serum clozapine levels: a review of their clinical utility</article-title><source>J Psychopharmacol</source><year>2003</year><volume>17</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">12870573</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>S</given-names></name><name><surname>Bishara</surname><given-names>D</given-names></name><name><surname>Besag</surname><given-names>FMC</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name></person-group><article-title>Clozapine-related EEG changes and seizures: dose and plasma-level relationships</article-title><source>Ther Adv Psychopharmacol</source><year>2011</year><volume>1</volume><fpage>47</fpage><lpage>66</lpage></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CH</given-names></name><name><surname>Chong</surname><given-names>SA</given-names></name><name><surname>Lambert</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>A</given-names></name><name><surname>Hackett</surname><given-names>LP</given-names></name><name><surname>Mahendran</surname><given-names>R</given-names></name><etal/></person-group><article-title>An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels</article-title><source>Int Clin Psychopharmacol</source><year>2005</year><volume>20</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">15812267</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>HY</given-names></name><name><surname>Su</surname><given-names>KP</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name></person-group><article-title>Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects?</article-title><source>J Clin Psychiatry</source><year>1999</year><volume>60</volume><fpage>408</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">10401922</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravasia</surname><given-names>S</given-names></name><name><surname>Dickson</surname><given-names>RA</given-names></name></person-group><article-title>Seizure on low-dose clozapine</article-title><source>Can J Psychiatry</source><year>1998</year><volume>43</volume><fpage>420</fpage><pub-id pub-id-type="pmid">9598281</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amann</surname><given-names>BL</given-names></name><name><surname>Pogarell</surname><given-names>O</given-names></name><name><surname>Mergl</surname><given-names>R</given-names></name><name><surname>Juckel</surname><given-names>G</given-names></name><name><surname>Grunze</surname><given-names>H</given-names></name><name><surname>Mulert</surname><given-names>C</given-names></name><etal/></person-group><article-title>EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects</article-title><source>Hum Psychopharmacol</source><year>2003</year><volume>18</volume><fpage>641</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">14696024</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Centorrino</surname><given-names>F</given-names></name><name><surname>Price</surname><given-names>BH</given-names></name><name><surname>Tuttle</surname><given-names>M</given-names></name><name><surname>Bahk</surname><given-names>WM</given-names></name><name><surname>Hennen</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>EEG abnormalities during treatment with typical and atypical antipsychotics</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">11772698</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillay</surname><given-names>SS</given-names></name><name><surname>Stoll</surname><given-names>AL</given-names></name><name><surname>Weiss</surname><given-names>MK</given-names></name><name><surname>Tohen</surname><given-names>M</given-names></name><name><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Banov</surname><given-names>MD</given-names></name><etal/></person-group><article-title>EEG abnormalities before clozapine therapy predict a good clinical response to clozapine</article-title><source>Ann Clin Psychiatry</source><year>1996</year><volume>8</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8743641</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Labelle</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Mahoney</surname><given-names>C</given-names></name></person-group><article-title>EEG hemispheric asymmetry as a predictor and correlate of short-term response to clozapine treatment in schizophrenia</article-title><source>Clin Electroencephalogr</source><year>2000</year><volume>31</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">10923202</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risby</surname><given-names>ED</given-names></name><name><surname>Epstein</surname><given-names>CM</given-names></name><name><surname>Jewart</surname><given-names>RD</given-names></name><name><surname>Nguyen</surname><given-names>BV</given-names></name><name><surname>Morgan</surname><given-names>WN</given-names></name><name><surname>Risch</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Clozapine-induced EEG abnormalities and clinical response to clozapine</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>1995</year><volume>7</volume><fpage>466</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">8555749</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Frequency of EEG abnormalities associated with clozapine (N=87)</p></caption><graphic xlink:href="pi-8-372-i001"/><table-wrap-foot><fn><p>EEG: electroencephalogram</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of clinical characteristics between those with and without EEG abnormalities associated with clozapine</p></caption><graphic xlink:href="pi-8-372-i002"/><table-wrap-foot><fn><p><sup>*</sup>p&#x0003c;0.05. EEG: electroencephalogram, SD: standard deviation, mths: months, wks: weeks</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Logistic regression analysis showing predictors of EEG abnormalities associated with clozapine</p></caption><graphic xlink:href="pi-8-372-i003"/><table-wrap-foot><fn><p><sup>*</sup>p&#x0003c;0.05, <sup>&#x02020;</sup>predictors from step 1 of backward conditional method. EEG: electroencephalogram</p></fn></table-wrap-foot></table-wrap></floats-group></article>